In late June 2026, Merck reported multiple oncology milestones, including U.S. FDA approval of KEYTRUDA and KEYTRUDA QLEX ...
Merck & Co., Inc. (NYSE:MRK) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 25, Merck & Co., Inc.
Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. But the breakthrough approval comes ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ ...
Merck MRK boasts more than six blockbuster drugs in its portfolio, with the blockbuster PD-L1 inhibitor Keytruda being the key top-line driver. Keytruda, approved for several types of cancer, alone ...
Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounted for more than 50% of the company’s ...
Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima didn’t exactly go their way. The Keytruda-Lenvima regimen, used on top ...
The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell ...
On Friday, Merck & Co Inc (NYSE:MRK) and Eisai Co Ltd (OTC:ESAIY) (OTC:ESALF) announced results from the Phase 3 LEAP-015 trial of Keytruda (pembrolizumab) plus Lenvima (lenvatinib), in combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results